NZB mice develop an age-related malignant expansion of a subset of B cells, B-1 cells, with autocrine production of IL-10. IL-10, a pleiotropic cytokine with anti-inflammatory properties, is a potent growth and survival factor for malignant B cells. To further examine the in vivo requirement for IL-10 in the development and expansion of malignant B-1 clones in NZB mice, we developed a strain of homozygous IL-10 knockout (KO) mice on an NZB background. The NZB IL-10 KO mice develop peritoneal B-1 cells with approximately the same frequency as heterozygous and wild-type littermates. In contrast, the development of malignant B-1 cells in the peripheral blood and spleen, observed in wild-type NZB, rarely occurred in the NZB IL-10 KO. Phenotypic analysis of surface marker expression in splenic B cells indicated that, in contrast to the NZB with malignant B-1 splenic lymphoma, the surface marker expression of NZB IL-10 KO splenic B cells indicated that the majority of the B cells were typical B-2 cells. In the absence of IL-10, spontaneously activated B cells and antiapoptotic gene expression were reduced and lymphoma incidence was decreased. These results indicate that IL-10 is a critical factor for the progression of this B-cell malignant disease.
Introduction
Identification of factors that contribute to the survival of malignant cells is crucial for designing specific intervention. Cytokines, because of their ability to prevent apoptosis, have been the target for therapies in several cancers. Interleukin 10 (IL-10) is able to regulate the production of other cytokines, act as a cell cycle regulator, and function as an antiapoptotic agent. Indeed, expression of IL-10 has been found to be elevated in many diseases and IL-10 promotes the survival of neurons and glial cells by promoting cell-survival signals.
1 B-1 cells are the major B-cell producers of IL-10, 2 and the most potent growthpromoting effect of IL-10 is seen on B-1 cells themselves. 3 Stimulation of autocrine production of IL-10 in B-1 cells has been found to promote their survival. 4 IL-10 has been found to be elevated in a variety of B-cell malignancies, including mantle cell lymphoma, 5, 6 AIDS-associated B lymphoma, 7 and in some patients with chronic lymphocytic leukemia (CLL). 8 Exogenous IL-10 has been found to stimulate the proliferation of mantle cell lymphoma cells. 9 Downregulation of IL-10 has been found to sensitize malignant B cells to apoptosis by chemotherapeutic agents. 10, 11 To study the importance of IL-10 in malignant B-1 disease, we established a malignant NZB-derived malignant B-1 cell line, which maintains the high IL-10 production in vitro. IL-10 is a necessary growth factor for these cells 12 and administration of antisense IL-10 oligonucleotides to the culture resulted in the inhibition of cell growth in a time-and dose-dependent manner. 13 In addition, subcutaneous antisense IL-10 delivery prevented the in vivo growth of transferred malignant B-1 cells. 14 To further investigate the role of IL-10 in the development and expansion of NZB malignant B-1 cells in vivo, we have generated NZB mice, which are genetically devoid of IL-10, through the inheritance of an inactivated IL-10 transgene. In the NZB IL-10 KO strain, the development of malignant B-cell disease and lymphoma was significantly reduced. Thus, IL-10 may function in the malignant B cells as a prosurvival signal.
Materials and methods

Mice
Dr Werner Muller (GBF, Braunschweig, Germany) kindly supplied heterozygous IL-10 KO C57BL/6 male mice. All wildtype NZB mice used for breeding were purchased from Jackson Labs (Bar Harbor, ME, USA). Heterozygous F1 mice were generated by the mating of the transgenic male mice with wildtype NZB females. The increase of NZB genetic background was achieved by the successive backcrossing of heterozygous offspring to wild-type NZB male or female mice. To maximize the inheritance of NZB background genes, a marker-assisted selection protocol (MASP) that identifies parental origin of various loci by detecting strain-specific differences in simple sequence length polymorphisms (SSLPs) was employed. 15 Individual backcross male mice, which expressed the highest percentage of NZB polymorphisms at the loci studied, were chosen for mating with parental NZB to generate the successive backcross generation. Only the loci that were heterozygous were analyzed by PCR in the next backcross generation offspring. The primers and PCR protocol were obtained from Research Genetics (Huntsville, AL, USA), and were chosen based on detectable polymorphisms between the NZB and the C57BL/6 (background of the IL-10 KO) strains spanning the 19 autosomal chromosomes. Information for some of the polymorphisms in the NZB genome was kindly supplied by Dr E Wakeland (Univ. Texas, Southwestern Med Ctr.), and a total of 50 loci were chosen for the study. The primer sequences can be accessed from the Whitehead Institute, Cambridge, MA, USA, via the Internet at http://www.genome.wi.mit.edu. The PCR protocol is a modification of that which is provided by Research Genetics, and was kindly supplemented by Dr R Metcalf (NIH, Bethesda, MD, USA). Briefly, tail DNA was amplified in a master mix containing 0.1 ml of each dNTP (0.05 mM final concentration), 0.1 ml of Amplitaq Gold DNA polymerase (0.025 U/ml final concentration), as well as PCR buffer and the specific up-and downstream SSLP primers. The PCR reaction was carried out using the following conditions : 1 cycle of 12 min  at 94   o   C, 30 repetitions of 15 s at 94  o C, 2 min at 58   o   C, 2 min at  72 o C, a final extension step of 8 min at 721C, and a final hold for 5 min at 85 o C. The products were run on a 4% agarose gel (Gibco, BRL), and visualized by ethidium bromide on a fluorimager. All PCR components (except primers) were purchased from Perkin-Elmer, and the reactions were carried out on a Perkin-Elmer 9600 thermal cycler. One band per primer represents homozygosity (from either parental strain) at that locus. Two bands per primer indicate the heterozygosity at that locus, one allele contributed by each parental strain.
The NZB IL-10 KO mice studied were produced by the intercross of a heterozygous male and female of the eighth backcross generation. In this manner, NZB ( þ / þ ), NZB ( þ /À), and NZB IL-10 KO (À/À) were generated. Due to the altered immune status of IL-10-deficient mice, 16 all mice were bred, raised, and maintained in sterile, germ-free conditions in barrier cages at the animal research facility at UMDNJ.
Identification of transgenic mice
At 4-5 weeks of age, pups were tail-clipped and DNA extracted and analyzed for the presence of the transgene. The procedure for PCR determination of transgenic mice was a modification of the protocol provided by Jackson Labs (Bar Harbor, ME, USA; http://aretha.jax.org/pub-cgi/protocols/). By employing three primers, the simultaneous detection of both wild-type (IL-10 þ / þ ) and transgenic alleles (IL-10 KO À/À) was possible. The two upstream primers IMRO87 and IMRO88 are specific for the endogenous and the affected allele, respectively. One common downstream primer, IMRO86, is specific for an area of exon I, which is unchanged by the transgene (all primers were purchased from Operon, Alameda, CA, USA). The primer sequences were IMRO86 5 0 -GTG GGT GCA GTT ATT GTC TTC CCG-3 0 , IMRO87 5 0 -GCC TTC AGT ATA AAA GGG GGA CC-3 0 , and IMRO88 5 0 -CCT GCG TGC AAT CCA TCT TG-3 0 ). The PCR reaction was carried out using 3 ml of tail DNA and a hot start PCR method. The hot start method is used to decrease any nonspecific products by physically separating the primers from the DNA and enzyme, until the temperature is high enough to inhibit nonspecific binding. The PCR reaction consists of one cycle of 941C for 3 min, 30 cycles of 941C for 30 s, 601C for 30 s, 721C for 30 s, followed by a final extension of 721C for 2 min. In combination, the three primers yield either one product, a 400 bp band, or a 200 bp band indicative of homozygous KO mice or wild-type mice, respectively. When the two bands, 200 and 400 bp, are present, this is indicative of a heterozygous mouse. All PCR components were purchased from Perkin-Elmer, and the PCR reaction was carried out on a Perkin-Elmer model 9600 thermal cycler. PCR products were run on a 2% agarose gel (Gibco BRL), and visualized by ethidium bromide on a fluorimager.
Determination of the presence of B-1 clones
Spleen, peripheral blood or peritoneal washout cells (PWC) from 8-12-month-old mice were studied. Three-color flowcytometric analysis was employed to determine B-1 cell percentages, and the antibodies used were goat anti-mouseIgM-FITC, mouse-anti-mouse-CD5 biotin (second step staining with streptavidin-phycoerythrin (PE)), and rat anti mouse-B220 Tri Color (TC). The B-1 population identified as malignant was usually IgM positive, B220 dull, and CD 5 dull or negative. A positive control included for staining was the previously derived malignant NZB B-1 cell line LNC. Additional four-color stain combinations included: rat anti-mouse CD19 FITC, goat antimouse IgM PE, rat anti-mouse B220 TC, and rat anti-mouse ICAM-1 biotin (second step streptavidin-APC). The other antibodies (conjugated to either FITC or RPE) employed included: rat-anti-mouse CD4, rat anti-mouse CD8, and mouse anti-mouse MHC Class II (recognizes I-A b/d ) and, in addition, rat anti-mouse Mac-1 biotin (second step staining either streptavidin-APC or TC). Antibodies were obtained from Caltag (San Francisco, CA, USA). Isotype controls were employed for all combinations. FACS data were acquired on a Becton Dickinson FACScaliber, using CellQuest software (BD, San Jose, CA, USA), and analysis of cell cycle was performed using ModFit LT software (Verity House Inc., Topsham, ME, USA). Cells were gated on forward and side scatter. In some cases, analysis was performed on cells which were electronically gated on B cells (IgM positive or CD19 positive), and profiles of the electronically gated cells displayed.
A feature of NZB malignant B-1 cells is the retention of entire chromosomes that result in a greater than normal complement of DNA, known as hyperdiploidy. For hyperdiploidy determination, DNA was stained with 500 ml of a hypotonic solution of propidium iodide, as previously described. 12 All cells were analyzed on an FACScan (Becton-Dickinson, Sunnyvale, CA, USA) and cell cycle was modeled using ModFitLT (Verity House Inc, Topsham, ME, USA). Idealized cell cycle distribution was displayed as shaded areas in the histogram: the shaded peak as the G0/G1 diploid and the nonshaded peak as the G0/G1 hyperdiploid.
Short-term culture of spleen cells NZB ( þ / þ ) and NZB IL-10 KO (À/À), 10-month old, were killed and the spleen cells obtained. Cells were washed in PBS and an aliquot assayed for the DNA content and surface marker expression, as described above. Cells were cultured (0.5 Â 10 6 ) for 72 h with and without LPS (20 mg/ml, Sigma Chemical, St Louis, MO, USA). Following 72 h of culture, cells were harvested and stained for surface marker expression as well as DNA content, both for aneuploidy determination as above, as well as sub-G1 cells (apoptotic).
Detection of specific mRNA by PCR
Total RNA was extracted from spleen or PWC using RNAzol (Tel Test, Friendswood, TX, USA) and reverse transcribed using random hexamers or oligo dT as the primers. Following reverse transcription, 20 ml of the cDNA was added to a PCR master mix, which contained specific primers. The PCR reactions were carried out at one cycle of 941C for 3 min, 35-40 cycles of 941C for 1 min, 551C for 1.5 min, and 721C for 2 min, followed by a final extension cycle of 721C for 2 min. The PCR products were run on a 2% agarose gel (Gibco BRL), and visualized with ethidium bromide on a fluorimager. The primer sequences and the expected size as determined by comparison to the reported cDNA sequence (gI number and nucleotides spanned by primers indicated) are presented in Table 1 . The primers were all checked by BLAST analysis (http://www.ncbi.nlm.nih.gov/ BLAST/) to ensure that they would not amplify another reported murine sequence. In addition, the amplicons (Fas, FasL, and BSAP) were sequenced for verification of product identity (data not shown) and the sequence obtained compared to the reported sequence. All amplicons were of the anticipated size with the exception of BSAP (B-cell-specific activator protein, pax 5). In this primer amplification, two products were identified and sequenced: the higher molecular weight product was of the expected sequence and the lower molecule weight product was a splice variant of BSAP. Splice variants for pax genes have previously been reported in which exon 2 has been spliced out. 17 PCR products were run on a 2% agarose gel (Gibco BRL), and visualized with ethidium bromide on a fluorimager (Molecular Dynamics, Sunnyvale, CA, USA). The amplicon density of the gene of interest was normalized to the amplicon density for the 'housekeeping' gene hypoxanthine phosphoribosyl transferase (HPRT). The densities of the bands were measured and normalized to HPRT using Image Quant software and expressed as the normalized ratio. All oligonucleotides were purchased from Operon (Alameda, CA, USA). In some cases, the amount of mRNA was further quantitated using RealTime PCR (Light cycler, Roche Diagnostics, Indianopolis, IN, USA) and Fast Start DNA SYBR Green I (Roche) with the primers listed in Table 1 .
Ribonuclease protection assay (RPA)
Templates for RPA for genes of interest (IL-12, IL-10, IL-1a, IL1b, IL-1RA, IL-18, IL-6, IFNg, MIF) were purchased from Pharmingen (San Diego, CA, USA) as multiplex kits, and used according to the manufacturer's instructions. Briefly, the template was in vitro transcribed with T7 RNA polymerase, labeled with 32 P-UTP, and hybridized to 5-10 mg of sample RNA. The protected bands were visualized using a phosphorimager (Molecular Dynamics, Sunnyvale, CA, USA). The bands were quantitated as a ratio of the observed protected fragment of the gene of interest to that of two housekeeping genes, L32 and GADPH, which were assayed at the same time in the same RPA lane.
Southern hybridization
Approximately, 10 mg of EcoR1-digested splenic DNA from NZB( þ / þ ), NZB( þ /À) or NZB IL-10 KO(À/À) mice was size separated by electrophoresis in 0.7% agarose gels and transferred to a Nylon membrane. Heavy-chain Ig rearrangement was detected by hybridizing the membrane to a radioactively labeled 0.8 kb EcoRI fragment probe specific for the JH region. 19 
Histological examination and image acquisition
Computerized images were obtained from either immunoperoxidase-labeled anti-CD79 alpha (DAKO) or H&E-stained glass slides using a Leica DM-RB compound microscope (Leica Microskopie und System Gmbh, Germany) and the 'Image Pro Plus Version 4.0 for Windows' image processing and analysis system (Media Cybernetics, Silver Spring, MD, USA). An Â 10 PL Fluotar lens was used for this application. The images were acquired through a DEI-750 CE Color camera (Optronics, Goleta, CA, USA) and the digitized images were processed in Microsoft Windows NT Workstation 4.0, in a Trinitron Pentium III computer. Optimum images were obtained, prior to digitization, by adjusting the brightness, sharpness, and contrast in order to reach the best definition.
Statistics
Sample group means and standard deviations were generated using Excel. Differences between groups were measured using an independent Student's t-test and SigmaPlot 3.0 software.
Results
Generation and characterization of NZB IL-10 KO mice
The availability of IL-10 KO mice on a background other than NZB required that a congenic strain be developed in which the IL-10 KO loci be introduced into the NZB background. The generation of the NZB IL-10 KO strain was facilitated by SSLP analysis to selectively backcross those mice with the highest percentage of NZB genetic background, which also carried the IL-10 KO locus. This technique, referred to as 'speed congenics', 20 allowed for a more rapid generation of the NZB IL-10 KO strain. The average number of genetic loci which are heterozygotes decreases with each successive backcross, but this is an average and individual male mice vary in the genetic Table 1 PCR primers, product size and gene identification number Analysis of B-cell lymphomas in NZB IL-10 KO J Czarneski et al composition contributed by the NZB-recipient strain. By random breeding at backcross #2, on average 25% of all loci are expected to be heterozygous 20 and the backcross would be 87.5% NZB genome. In contrast, in our breeding using MASP, beginning with backcross #2 (also referred to as N3 20 ), a male identified as carrying the IL-10 KO loci (as a heterozygote) was selected for the generation of backcross #3, since this male had only 20% heterozygous loci (based on the limited number of 50 SSLPs studied), which would result in 90% NZB genome. Thus, by selecting male backcross mice that have the highest NZB alleles (homozygous NZB), the NZB genetic background can be increased. For the generation of the congenic strain NZB IL-10 KO, individual backcross male mice (in backcross #2, #3, and #4) identified as the highest NZB genetic background were employed for the subsequent backcross generation. With the use of a limited number of SSLP primer pairs, the estimate of 100% NZB alleles occurred in a male of backcross #4. To ensure that the IL-10 KO strain was entirely NZB background genes, backcrossing was continued and backcross #8 mice (even by random breeding, these would be 99.81% NZB genome) were brother sister mated to generate the NZB IL-10 KO mice.
Cytokines and transcription factors in NZB IL-10 KO mice
PCR analysis of gene expression in splenic RNA obtained from barrier-housed NZB IL-10 KO and wild-type NZB demonstrated that NZB IL-10 KO spleens had elevated RNA for inflammatory mediators such as IL-6, IL-12, and TNFa, but this was not significant (Figure 1) . These values are normalized and reported as a ratio of the level of expression relative to the housekeeping gene HPRT. Levels of TNF message were further quantitated by real-time PCR, and no significant difference between NZB and NZB IL-10 KO splenic RNA was observed (data not shown). To further study cytokine expression in the NZB IL-10 KO mice, a ribonuclease protection assay (RPA) was employed to quantitate the amount of RNA for inflammatory mediators present in the NZB and NZB IL-10 KO spleens (Figure 2) . The NZBIL-10 KO was greatly decreased in IL-10, but had increased expression of many cytokines involved in inflammation. The increased splenic RNA levels as determined by RPA in NZB IL-10 KO spleens were significantly higher than the NZB in the case of IFNg and IL-1b. (KKKKKKKKKKKKKKKKKKKpKKKKK). In barrier-housed NZB IL-10 KO mice, only modest inflammation was observed in the colon (histology not shown). This is in agreement with the observation by Kuhn et al 16 that housing IL-10 KO mice under specific-pathogen-free conditions can significantly reduce the incidence and severity of bowel inflammation. The NZB IL-10 KO were similar to the parental NZB strain in that increased levels of anti-DNA autoantibodies, particularly IgM, were detected in the sera when compared to the nonautoimmune DBA/2 levels ( Figure 3) . The lack of endogenous IL-10 does not result in apparent skewing towards the TH1 phenotype or a decreased autoantibody production.
Cell surface markers in NZB IL-10 KO mice
We have previously shown that, as autoimmune-prone NZB mice age, they develop a dominant clone of B-1 cells with a unique set of surface markers, which include: IgM positive, Mac 1 dull, CD5 dull, and B220 dull. Flow-cytometric analysis of spleen cells from representative NZB and NZB IL-10 KO 9-12-month-old mice demonstrated that, as expected, NZB spleens contain a large population of B cells with characteristics consistent with a malignant clonal expansion of B-1 cells. The NZB spleen had more B cells (positive for IgM (Figure 4a) ) than the NZB IL-10 KO spleen. In contrast, the NZB IL-10 KO spleen had more cells that were bright for CD5, the phenotype of most T cells in the spleen (Figure 4b ). In the gated B-cell population (IgM positive), there were no cells bright for CD5; however, there was a population dull for CD5 expression present predominantly in the NZB strain and noticeably absent in the NZB IL-10 KO (Figure 4b ). Dull CD5 expression is the membrane phenotype of B-1 cells. Thus, splenic B cells in the NZB IL-10 KO mice had reduced presence of the unique population of B cells characteristic of B-cell malignancies in aged NZB. These cells can be further identified as unique malignant B cells because of their reduced expression of B220. In total spleen cells and gated B cells, only the NZB demonstrated the presence of a population of cells which are dull for B220 expression (Figure 4c) . B-1 cells demonstrate a low but detectable expression of CD11b (Mac1). The NZB spleen and not the NZB IL-10 KO spleen had a B-cell population that was Mac1 dull (Figure 4d) . Thus, the NZB IL-10 KO spleen did not have the NZB characteristic expansion of B-1 cells, as determined by flow-cytometric analysis of membrane marker expression.
As NZB mice age, the malignant B-1 clones have been found to have chromosomal abnormalities and the most common presentation is aneuploidy. In addition, the consistent phenotype of the malignant B-1 cells in NZB is decreased B220 expression. 21 Analysis of the DNA content and membrane marker expression of spleens obtained from three representative NZB IL-10 KO mice failed to show the characteristic malignant B-1 clones normally observed in wild-type NZB ( Figure 5 ). The Analysis of gene expression. Summary of analysis of RNA expression in the spleens of 8-10-month-old mice. The top portion shows representative gel slices of the PCR amplicons in the size region of 100-400 bp. All PCR amplicons were of the expected size. The BSAP upper band is the full-length message and this band was subjected to densitometric analysis. The bottom graph shows the mean cytokine ratios (normalized to the housekeeping gene HPRT) of the densitometric analysis of gels. Hatched columns are RNA expression ratios of NZB IL-10 KO À/À and solid columns are NZB þ / þ . Columns are means and standard error of the means.
Analysis of B-cell lymphomas in NZB IL-10 KO
J Czarneski et al high B220 expression present in the majority of splenic B cells from non-NZB strains was observed in the NZB IL-10 KO strain. Consistent with this finding, the spleens of NZB IL-10 KO mice possessed the normal DNA content. The summary of the average percentages of splenic subpopulations observed in NZB and NZB IL-10 KO mice indicates a significant increase in T cells and macrophages in the spleens of NZB IL-10 KO mice when compared to the wild-type NZB (Figure 6a ). The NZB IL-10 KO spleens were decreased in the presence of B-1 cells and significantly decreased in two characteristics found in the malignant B cells, aneuploidy and B cells, which are dull for B220 expression (Figure 6a/b) . In contrast, no significant difference between NZB and NZB IL-10 KO mice was observed in the peritoneal cells (Figure 6c, d ).
Splenic histopathology of NZB IL-10 KO
The presence of malignant B-1 clones could be detected as abnormal pathology in stained spleen sections of NZB with Ribonuclease Protection Assay: The top portion is a representative RPA in which the lack of a protected IL-10 band in the NZB IL-10 KO spleen is indicated in the dotted box. Lanes are labeled as to the source of RNA. The control is supplied in the kit and the last lane is a mixture of murine RNA obtained from our lab. The identification of the protected fragment is on the left. The bottom graph is the mean normalized RPA ratios for NZB IL-10 KO spleen (n ¼ 7) in the gray columns and the mean of the NZB wild type (n ¼ 4) in the dark columns.
Figure 3
Autoantibody levels in the sera of 8-12-month-old mice. Summary of mean ELISA values of sera from NZB, NZB IL-10 KO and DBA/2 mice. At least four mice were studied in each group. The ELISA plates were coated with dsDNA and the developing antibodies were isotype specific.
Figure 4
Flow-cytometric analysis of spleens from individual NZB and NZB IL-10 KO mice. Spleen cells were obtained from 11-monthold mice and stained for surface expression of IgM, CD5, B220, and (Figure 7d) , which was not observed in the NZB IL-10 KO (Figure 7a-d) . The spleens of NZB mice with malignant B clones had a loss of splenic architecture with a homogenous population of B cells throughout the spleen and the loss of germinal centers (Figure 7a ). In contrast, the NZB IL-10 KO spleen had normal splenic architecture and B cells in the germinal centers (Figure 7a ). In addition, the lymphocytosis observed in the blood was evident in the splenic blood vessels of NZB only (Figure 7c ). The histopathologic characteristics of the neoplasia in the NZB mice were consistent with a neoplasm of mature B cells, either a small B-cell lymphoma or a splenic mantle zone lymphoma. 22 The clones that could be detected in the spleen on the basis of abnormal DNA content and surface markers were also defined as a clonal population by Southern analysis of non-germline heavy chain immunoglobulin rearrangements in NZB (both wild-type and heterozygous), but no clonal populations were observed by Southern analysis in the NZB IL-10 KO spleen (data not shown). The NZB mice developed a B-cell malignancy characterized by the presence of aneuploid B-1 cells in multiple tissues in the periphery. The overall incidence of B-cell lymphoma in the NZB IL-10 KO strain was greatly reduced. In the group of aged NZB IL-10 KO mice, there was a small percentage (10%) of the mice studied that had a B-1 cell lymphoma in the spleen. This was a much lower percentage than that observed in the wild-type NZB (90%). Thus, the role of IL-10 in NZB mice appears to be as an autocrine survival factor for malignant B cells.
Activation markers in NZB and NZB IL-10 KO
The malignant B-1 cells in NZB mice appear to be activated B cells. All the NZB B cells (mainly malignant B-1) express high levels of ICAM-1 (Figure 8a ). In contrast, the ICAM-1 expression was reduced in the B cells of the NZB IL-10 KO strain. In The above data suggested that, in NZB wild-type mice, B cells are rescued from activation-induced cell death. The fact that NZB IL-10 KO mice were greatly reduced in the incidence of malignant B-1 clonal development also suggested that IL-10 may protect B cells from apoptosis following signals for activation. To study this further, B cells were studied for the ability of IL-10 to protect from apoptosis following in vitro exposure to LPS. Splenic B cells were exposed to LPS for 72 h and then analyzed for the expression of ICAM-1. The ICAM-1 expression increased in the NZB IL-10 KO B cells following LPS stimulation, to near the level observed in the ex vivo untreated wild-type NZB B cells (Figure 8b ). Both the NZB and the NZB IL-10 KO mice had high levels of ICAM-1 expression following in vitro exposure to LPS activation. Interestingly, the hyperdiploid B population nearly doubled in the NZB, suggesting that the malignant B cells had a selective survival advantage in response to LPS. In contrast, the very small percentage of malignant B cells (5.78%) in the NZB IL-10 KO ex vivo spleen was eliminated by 72 h in vitro exposure to LPS activation signals.
To determine if IL-10 may indirectly effect the levels of antiapoptotic genes, several genes were studied for RNA expression by semiquantitative PCR (Figure 9 ). The levels of IL-10, as expected, were significantly decreased in the NZB IL-10 KO strain. The antiapoptotic gene bcl-xL was reduced in the NZB IL-10 KO strain. The reduced development of malignant B cells in the NZB IL-10 KO strain may be related to the reduced expression of antiapoptotic genes, particularly bcl-xL.
Discussion
In this manuscript, we report the characteristics of an NZB congenic strain devoid of IL-10. We found that NZB IL-10 KO mice were similar to wild-type NZB mice in that both types of NZB mice have hyper IgM in sera as well as anti-DNA autoantibodies, predominantly of the IgM isotype, that are greatly elevated when compared to the non-autoimmune DBA/2 strain. The autoimmune aspects of NZB mice studied thus far are not significantly altered by the lack of IL-10. Thus, the autoimmune aspects of NZB mice, which are detected from a Immunohistology and the presence of leukemia. Spleen sections (a-c) and peripheral blood (d) were obtained from NZB þ /À and NZB IL-10 KO À/À mice (11-month-old mice). The top sections (a) were stained with anti-CD79 alpha, a pan-B marker. The NZB þ /À spleen had diffuse staining throughout the spleen. In contrast, the NZB IL-10 KO À/À had visible germinal centers. The bottom two panels are H&E-stained sections (b, c) demonstrating the loss of splenic architecture in the NZB þ /À and the presence of lymphocytes in blood vessels in the NZB þ /À spleen only. The DNA content of the NZB ILyoung age, are similar in NZB and NZB IL-10 KO mice. In addition, the NZB IL-10 KO strain is similar to other IL-10 KO strains in that there is modest inflammation of the bowels (manuscript in preparation). In contrast, the late-onset B cell lymphomas that develop in wild-type NZB were significantly reduced in the NZB IL-10 KO strain.
The results from analysis of NZB IL-10 KO mice indicate that the presence of malignant B cells with characteristic surface markers was greatly reduced when compared to wild-type agematched NZB mice. Thus, the lack of IL-10 appears to prevent the survival of malignant B cells. Histological analysis of spleens for the presence of lymphoma indicated that NZB IL-10 KO mice were different from intact NZB mice. In NZB mice with IL-10, the splenic architecture was replaced by the expansion of malignant B cells, and this was not observed for the most part in spleens from age-matched NZB IL-10 KO mice. Analysis of the surface markers present on spleen cells also indicated that the characteristic NZB malignant B clones, which are dull for Mac 1, CD5, and B220, and bright for IgM, were significantly reduced in the NZB IL-KO spleen. The malignant B cells in the spleens of NZB mouse have previously been characterized as B-1 cells, 23 and in particular to be B-1a cells, as defined. 24 However, the presence of CD5 on these cells is very dull. In this manuscript, we describe the malignant cells as B-1 cells, based on the cumulative phenotype of the cells. Our previous studies over the past have indicated that, in NZB spleens, the aneuploid malignant B cells are B-1 cells which are dull for CD5, Mac-1, and B220, and these malignant B cells were greatly reduced or not present in the NZB IL-10 KO spleens. B-1 cells are found predominantly in the peritoneum of most strains of adult mice. Peritoneal B-1 cell percentages in the NZB IL-10 KO mice were not reduced when compared to wild-type NZB. This is consistent with the findings in the peritoneum of other IL-10 KO strains. 16 This is in contrast to earlier studies by Ishida et al, which found that administration of anti-IL-10 antibodies to (NZB/W) F1 mice from birth to 8-10 months of age can significantly decrease the number of B-1 cells. 25 However, this might have possibly been due to the inhibition of B-1 cell growth by the resultant overexpression of IFN-g in the anti-IL-10-treated mice. The NZB IL-10 KO spleens had higher expression of several cytokines involved in inflammatory processes including IFNg, IL-1b, TNFa, IL-6, and IL-12. However, in vivo injections of LPS greatly increased the expression of inflammatory cytokines in the spleens of the NZB IL-10 KO when compared to wild-type NZB (data not shown), indicating that IL-10 is required as an anti-inflammatory agent.
The NZB B-1 expansion has been considered a model of Bcell lymphoproliferative disease. The NZB malignant B-1 expansion has many similarities to the human disease CLL (reviewed in Chiorazzi and Ferrarini 26 ), which is also an ageassociated malignant B-cell expansion of self-reactive, 27 often anti-RBC-specific, 28 CD5 þ B-1 clones, which display defects in the induction of programmed cell death 29 and frequently have chromosomal instability. 30, 31 Abnormal surface expression of Bcell markers has been found in CLL, including decreased B220 expression. 32 The failure to undergo apoptosis may be a factor in the indolent nature of the disease, with a median survival of more than 10 years. NZB malignant B-1 clones (found in the spleen, peritoneum, blood, and other tissues) are characterized by the presence of extra chromosomes and chromosomal translocations. In the NZB IL-10 KO strain, only the peritoneum had a small percentage of hyperdiploid malignant B-1 cells. This suggests that IL-10 is required for clonal expansion, which, when present, results in lymphoma/leukemia. In the intact NZB mouse in which the malignant B-1 cells produce IL-10, the ability to survive outside the peritoneum is crucial for the development of B-cell lymphoma (BCL). It appears that IL-10 may not be the factor responsible for the development of the malignant B cells in NZB, but rather a factor that protects these B-1 cells from apoptosis. IL-10 is now recognized as an antiapoptotic factor. In the Cancer Genome Anatomy Project using the Gene Finder results for genes responsible for apoptosis-inhibitory activity, 21 genes are listed, one of which is IL-10 (http://cgap.nci.nih.gov). In the present study, we have found that IL-10 is a critical factor for the sustained clonal development of malignant B cells. The IL-10 is not derived from the microenvironment, but rather produced by the malignant B-1 cells themselves. The fact that IL-10 is a pivotal factor controlling B-1 cell survival has been supported by studies with human B cells in which increasing IL-10 production in normal human B cells, accomplished by introducing CD5 signaling, resulted in protection from apoptosis. 4 This previous study suggests that IL-10 protects B cells from apoptosis and B-1 cells, in particular, via signaling through CD5, which upregulates IL-10. While many studies have found that IL-10 is antiapoptotic, 33, 34 others have not found this to be the case. 35 Recently, agents that decrease IL-10 have found clinical use because of their ability to induce malignant B cells to undergo apoptosis. Rituximab was found to inhibit IL-10 production in non-Hodgkin's lymphoma and sensitize the malignant B cells to therapeutic drugs. 10 IL-10 has been found to be a protective factor which enhances growth progression in several BCLs through an autocrine loop. 36 One possible mechanism by which IL-10 protects against apoptosis may be via upregulation of antiapoptotic factors, particularly of the bcl-2 family. 37 In this manuscript, a member of the bcl-2 family, the antiapoptotic gene bcl-xL 38 was found to have decreased expression in the NZB IL-10 KO spleen, providing a possible mechanism for the antiapoptotic effects of IL-10.
Analysis of membrane markers on the B cells in NZB and NZB IL-10 KO mice demonstrated that the presence of activated B cells was predominantly detected in the wild-type NZB mice. The B cells of wild-type NZB expressed both high MHC Class II and ICAM-1, both markers of B-cell activation. 39 In contrast, B cells from the NZB IL-10 KO were reduced in these markers, particularly ICAM-1. While the B cells in NZB IL-10 KO spleens may have reduced ICAM-1 expression relative to wild-type B cells, previous studies of ICAM-1 expression in C57BL/6 wildtype and IL-10 KO nonlymphoid organs have shown no difference, and ICAM-1 is upregulated following LPS activation in vivo in both strains. 40 Our data suggest that, in NZB B cells, IL-10 may be responsible for the protection from B-cell activation-induced cell death. Indeed, LPS exposure in shortterm cultures of B cells from NZB IL-10 KO mice resulted in the upregulation of ICAM-1, but a selective decrease in malignant B cells. In contrast, in the wild-type NZB, the malignant B-cell numbers increased following in vitro exposure to LPS. The present studies indicate that IL-10 plays a pivotal role in maintaining the widespread growth of the malignant B-1 clone, which results in a B-cell lymphoproliferative disease in NZB mice. IL-10 may prevent the death of activated B cells. Targeting IL-10 and/or IL-10-mediated events may prove beneficial in the regulation of malignant B-cell growth in a subset of B-cell lymphomas.
